Coronary Stenting: Reflections on a 35-Year Journey.


Journal

The Canadian journal of cardiology
ISSN: 1916-7075
Titre abrégé: Can J Cardiol
Pays: England
ID NLM: 8510280

Informations de publication

Date de publication:
10 2022
Historique:
received: 01 03 2021
revised: 12 07 2021
accepted: 14 07 2021
pubmed: 11 8 2021
medline: 13 10 2022
entrez: 10 8 2021
Statut: ppublish

Résumé

Stenting was introduced as a therapy for coronary artery disease 35 years ago, and is currently the most commonly performed minimally invasive procedure globally. Percutaneous coronary revascularization, initially with plain old balloon angioplasty and later with stenting, has dramatically affected the outcomes of acute myocardial infarction and acute coronary syndromes. Coronary stenting is probably the most intensively studied therapy in medicine on the basis of the number of randomized clinical trials for a broad range of indications. Continuous improvements in stent materials, design, and coatings concurrent with procedural innovations have truly been awe-inspiring. The story of stenting is replete with high points and some low points, such as the initial experience with stent thrombosis and restenosis, and the more recent disappointment with bioabsorbable scaffolds. History has shown rapid growth of stent use with expansion of indications followed by contraction of some uses in response to clinical trial evidence in support of bypass surgery or medical therapy. In this review we trace the constantly evolving story of the coronary stent from the earliest experience until the present time. Undoubtedly, future iterations of stent design and materials will continue to move the stent story forward.

Identifiants

pubmed: 34375695
pii: S0828-282X(21)00623-1
doi: 10.1016/j.cjca.2021.07.224
pii:
doi:

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

S17-S29

Informations de copyright

Copyright © 2021 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Auteurs

Bradley H Strauss (BH)

Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; University of Toronto, Toronto, Ontario, Canada. Electronic address: bradley.strauss@sunnybrook.ca.

Jean-François Tanguay (JF)

Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada.

Fabien Picard (F)

Cardiology Department, Assistance Publique-Hôpitaux de Paris, Hôpital Cochin, Paris, France.

Serge Doucet (S)

Montreal Heart Institute, University of Montreal, Montreal, Quebec, Canada.

Marie-Claude Morice (MC)

Department of Cardiology, Institut Hospitalier Jacques Cartier, Ramsay Générale de Santé, Massy, France.

Gabby Elbaz-Greener (G)

Schulich Heart Program, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Cardiology Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH